Cabaletta Bio, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the period ended June 30, 2026, disclosing significant losses, a going concern warning, and ongoing clinical-stage operations centered on its lead product candidate resecabtagene autoleucel.

Key Highlights

  • Going concern warning: The company disclosed that it "identified conditions that raise substantial doubt about our ability to continue as a going concern."
  • Cash runway concern: According to the filing, if the company is unable to secure additional funding that enables operations into mid-2027, it may be forced to delay, reduce, or discontinue product development programs or other operations.
  • Shares outstanding: As of August 7, 2026, the registrant had 169,545,445 shares of common stock, $0.00001 par value per share, outstanding.
  • Lead product candidate: The company is conducting Phase 1/2 RESET clinical trials for resecabtagene autoleucel (formerly referred to as CABA-201), referred to as rese-cel.
  • Manufacturing dependence: The filing states the company is "highly dependent" on relationships with Lonza Houston Inc. and Cellares Corporation for current manufacturing needs.
  • Additional funding required: The company disclosed it "will need to raise substantial additional funding before we can expect to complete development of any of our product candidates or generate any revenues from product sales."

Cabaletta Bio's Q2 2026 Disclosures: Going Concern, Clinical Programs, and Funding Needs

Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, filed its Form 10-Q for the quarterly period ended June 30, 2026. The filing identifies the company as a non-accelerated filer and smaller reporting company incorporated in Delaware, operating from its principal offices at 2929 Arch Street, Suite 600, Philadelphia, PA 19104.

A central disclosure in the filing is the going concern warning. The company stated it has "incurred significant losses since our inception" and anticipates continuing to incur significant losses "for the foreseeable future." The filing further disclosed that without additional funding enabling operations into mid-2027, the company may be forced to delay, reduce, or discontinue its product development programs. The company's primary clinical focus is on rese-cel, which is being evaluated in its Phase 1/2 RESET (Restoring Self-Tolerance) clinical trials. The filing also disclosed that the company is reliant on intellectual property licensed from Nanjing IASO Biotherapeutics Co., Ltd., and that termination of that license "would result in the loss of significant rights, which would have a material adverse effect on our business."

The filing highlights several operational risks, including dependence on Lonza Houston Inc. and Cellares Corporation for manufacturing, potential difficulties in patient enrollment for the RESET clinical trials, and competition from other companies developing similar products. The company also noted that "results of earlier studies may not be predictive of future study or trial results." The filing contains forward-looking statements, which the company characterized as subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements.

What Was Disclosed

Cabaletta Bio's 10-Q for the period ended June 30, 2026 disclosed a going concern condition, continued net losses, dependence on third-party manufacturers and a licensed intellectual property agreement, and the need for substantial additional funding to continue operations and advance its rese-cel clinical program.